CCM
NTLA icon

CAAS Capital Management’s Intellia Therapeutics NTLA Stock Holding History

CAAS Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-170,000
Closed -$13.6M – 1201
2021
Q1 		$13.6M Hold
170,000
– – 0.15% 166
2020
Q4 		$9.25M Buy
+170,000
New +$6.17M 0.09% 218

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAAS Capital Management's NTLA Position: Q1 2023 in Review

CAAS Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 15,000 shares — an estimated $523K sold.

CAAS Capital Management first reported a position in NTLA in Q2 2021 and held it in 2 quarters. The position peaked at $5.67M in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • CAAS Capital Management reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Intellia Therapeutics shares in Q1 2023, an estimated $523K.
  • CAAS Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Intellia Therapeutics position peaked at $5.67M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.